O	0	8	Symptoms
O	9	12	and
O	13	16	QOL
O	17	19	as
O	20	30	Predictors
O	31	33	of
O	34	49	Chemoprevention
O	50	59	Adherence
O	60	62	in
O	63	66	NRG
O	67	75	Oncology
O	75	76	/
O	76	81	NSABP
O	82	87	Trial
O	88	89	P
O	89	90	-
O	90	91	1
O	91	92	.

O	93	102	Tamoxifen
O	103	111	provides
O	112	113	a
O	114	116	50
O	116	117	%
O	118	127	reduction
O	128	130	in
O	131	134	the
O	135	144	incidence
O	145	147	of
O	148	154	breast
O	155	161	cancer
O	162	163	(
O	163	165	BC
O	165	166	)
O	167	172	among
O	173	177	high
O	177	178	-
O	178	182	risk
O	183	188	women
O	188	189	,
O	190	193	yet
O	194	198	many
O	199	201	do
O	202	205	not
O	206	212	adhere
O	213	215	to
O	216	219	the
O	220	224	five
O	224	225	-
O	225	229	year
O	230	236	course
O	237	239	of
O	240	247	therapy
O	247	248	.

O	249	254	Using
O	255	258	the
O	259	270	prospective
O	271	277	double
O	277	278	-
O	278	283	blind
O	284	292	National
O	293	301	Surgical
O	302	310	Adjuvant
O	311	317	Breast
O	318	321	and
O	322	327	Bowel
O	328	335	Project
O	336	337	P
O	337	338	-
O	338	339	1
O	340	345	study
O	345	346	,
O	347	349	we
O	350	359	evaluated
O	360	367	whether
O	368	379	participant
O	379	380	-
O	380	388	reported
O	389	397	outcomes
O	398	402	were
O	403	413	associated
O	414	418	with
O	419	423	drug
O	424	433	adherence
O	434	437	and
O	438	445	whether
O	446	454	baseline
O	455	465	behavioral
O	466	470	risk
O	471	478	factors
O	479	487	modified
O	488	493	those
O	494	506	associations
O	506	507	.

O	508	509	P
O	509	510	-
O	510	511	1
O	512	524	participants
O	525	529	were
O	530	538	randomly
O	539	547	assigned
O	548	550	to
B-control	551	558	placebo
O	559	561	vs
B-intervention	562	571	tamoxifen
O	572	573	(
O	573	577	20mg
O	577	578	/
O	578	581	day
O	581	582	)
O	582	583	.

O	584	589	Mixed
O	590	597	effects
O	598	606	logistic
O	607	617	regression
O	618	621	was
O	622	626	used
O	627	629	to
O	630	638	evaluate
O	639	646	whether
O	647	655	baseline
O	656	658	or
O	659	664	three
O	664	665	-
O	665	670	month
O	671	673	SF
O	673	674	-
O	674	676	36
O	677	684	quality
O	685	687	of
O	688	692	life
O	693	694	(
O	694	697	QOL
O	697	698	)
O	699	705	mental
O	706	709	and
O	710	718	physical
O	719	728	component
O	729	738	summaries
O	739	740	(
O	740	743	MCS
O	743	744	,
O	745	748	PCS
O	748	749	)
O	749	750	,
O	751	754	and
O	755	766	participant
O	766	767	-
O	767	775	reported
O	776	784	symptoms
O	785	786	(
O	786	797	gynecologic
O	797	798	,
O	799	808	vasomotor
O	808	809	,
O	810	816	sexual
O	816	817	,
O	818	821	and
O	822	827	other
O	827	828	)
O	829	838	predicted
O	839	841	12
O	841	842	-
O	842	847	month
O	848	852	drug
O	853	862	adherence
O	863	864	(
O	864	866	76
O	866	867	-
O	867	870	100
O	870	871	%
O	872	874	of
O	875	883	assigned
O	884	894	medication
O	894	895	)
O	895	896	.

O	897	900	The
O	901	911	evaluation
O	912	921	accounted
O	922	925	for
O	926	929	age
O	929	930	,
O	931	940	treatment
O	940	941	,
O	942	951	estimated
O	952	958	breast
O	959	965	cancer
O	966	970	risk
O	970	971	,
O	972	981	education
O	981	982	,
O	983	991	baseline
O	992	999	smoking
O	999	1000	,
O	1001	1008	alcohol
O	1009	1020	consumption
O	1020	1021	,
O	1022	1025	and
O	1026	1033	obesity
O	1033	1034	.

O	1035	1038	All
O	1039	1050	statistical
O	1051	1056	tests
O	1057	1061	were
O	1062	1065	two
O	1065	1066	-
O	1066	1071	sided
O	1071	1072	.

B-eligibility	1073	1085	Participants
I-eligibility	1086	1094	enrolled
I-eligibility	1095	1097	at
I-eligibility	1098	1103	least
I-eligibility	1104	1109	three
I-eligibility	1110	1115	years
I-eligibility	1116	1122	before
I-eligibility	1123	1128	trial
I-eligibility	1129	1139	unblinding
I-eligibility	1140	1143	and
I-eligibility	1144	1151	without
I-eligibility	1152	1161	medically
I-eligibility	1162	1171	indicated
I-eligibility	1172	1187	discontinuation
I-eligibility	1188	1194	before
I-eligibility	1195	1197	12
I-eligibility	1198	1204	months
O	1205	1209	were
O	1210	1218	eligible
O	1219	1222	for
O	1223	1226	the
O	1227	1234	present
O	1235	1243	analyses
O	1244	1245	(
O	1245	1246	n
O	1247	1248	=
B-total-participants	1249	1251	10
I-total-participants	1252	1255	576
O	1255	1256	)
O	1256	1257	.

O	1258	1260	At
O	1261	1263	12
O	1264	1270	months
O	1270	1271	,
O	1272	1274	84
O	1274	1275	.
O	1275	1276	3
O	1276	1277	%
O	1278	1282	were
O	1283	1291	adherent
O	1291	1292	.

O	1293	1306	Statistically
O	1307	1318	significant
O	1319	1329	predictors
O	1330	1332	of
O	1333	1342	adherence
O	1343	1347	were
O	1347	1348	:
B-outcome	1349	1354	three
I-outcome	1354	1355	-
I-outcome	1355	1360	month
I-outcome	1361	1364	MCS
O	1365	1366	(
O	1366	1370	odds
O	1371	1376	ratio
O	1377	1378	[
O	1378	1380	OR
O	1380	1381	]
O	1382	1383	=
O	1384	1385	1
O	1385	1386	.
O	1386	1388	15
O	1389	1392	per
O	1393	1395	10
O	1396	1402	points
O	1402	1403	,
O	1404	1406	95
O	1406	1407	%
O	1408	1418	confidence
O	1419	1427	interval
O	1428	1429	[
O	1429	1431	CI
O	1431	1432	]
O	1433	1434	=
O	1435	1436	1
O	1436	1437	.
O	1437	1439	06
O	1440	1442	to
O	1443	1444	1
O	1444	1445	.
O	1445	1447	25
O	1447	1448	)
O	1448	1449	;
B-outcome	1450	1455	three
I-outcome	1455	1456	-
I-outcome	1456	1461	month
I-outcome	1462	1473	gynecologic
I-outcome	1474	1482	symptoms
O	1483	1488	among
O	1489	1497	moderate
O	1498	1505	alcohol
O	1506	1514	drinkers
O	1515	1516	(
O	1516	1518	OR
O	1519	1520	=
O	1521	1522	.
O	1522	1524	79
O	1524	1525	,
O	1526	1528	95
O	1528	1529	%
O	1530	1532	CI
O	1533	1534	=
O	1535	1536	0
O	1536	1537	.
O	1537	1539	72
O	1540	1542	to
O	1543	1544	0
O	1544	1545	.
O	1545	1547	88
O	1547	1548	)
O	1548	1549	;
B-outcome	1550	1558	baseline
I-outcome	1559	1568	vasomotor
I-outcome	1569	1577	symptoms
O	1578	1583	among
O	1584	1596	participants
O	1597	1605	assigned
O	1606	1615	tamoxifen
O	1616	1617	(
O	1617	1619	OR
O	1620	1621	=
O	1622	1623	.
O	1623	1625	88
O	1625	1626	,
O	1627	1629	95
O	1629	1630	%
O	1631	1633	CI
O	1634	1635	=
O	1636	1637	0
O	1637	1638	.
O	1638	1640	80
O	1641	1643	to
O	1644	1645	0
O	1645	1646	.
O	1646	1648	97
O	1648	1649	)
O	1649	1650	;
O	1651	1654	and
B-outcome	1655	1660	three
I-outcome	1660	1661	-
I-outcome	1661	1666	month
I-outcome	1667	1673	sexual
I-outcome	1674	1682	symptoms
O	1683	1688	among
O	1689	1696	younger
O	1697	1709	participants
O	1710	1711	(
O	1711	1713	OR
O	1714	1715	=
O	1716	1717	.
O	1717	1719	89
O	1720	1722	at
O	1723	1726	age
O	1727	1729	41
O	1730	1735	years
O	1735	1736	,
O	1737	1739	95
O	1739	1740	%
O	1741	1743	CI
O	1744	1745	=
O	1746	1747	0
O	1747	1748	.
O	1748	1750	80
O	1751	1753	to
O	1754	1755	0
O	1755	1756	.
O	1756	1758	99
O	1758	1759	)
O	1759	1760	.

O	1761	1764	The
O	1765	1774	strongest
O	1775	1786	association
O	1787	1790	was
O	1791	1795	with
B-outcome	1796	1801	three
I-outcome	1801	1802	-
I-outcome	1802	1807	month
I-outcome	1808	1813	other
I-outcome	1814	1822	symptoms
O	1823	1824	(
O	1824	1826	OR
O	1827	1828	=
O	1829	1830	.
O	1830	1832	77
O	1832	1833	,
O	1834	1836	95
O	1836	1837	%
O	1838	1840	CI
O	1841	1842	=
O	1843	1844	0
O	1844	1845	.
O	1845	1847	63
O	1848	1850	to
O	1851	1852	0
O	1852	1853	.
O	1853	1855	93
O	1855	1856	)
O	1856	1857	.

B-outcome	1858	1861	PCS
O	1862	1865	was
O	1866	1869	not
O	1870	1880	associated
O	1881	1885	with
O	1886	1895	adherence
O	1895	1896	.

O	1897	1904	Symptom
O	1905	1908	and
O	1909	1912	QOL
O	1913	1925	associations
O	1926	1930	were
O	1931	1934	not
O	1935	1943	modified
O	1944	1946	by
O	1947	1954	smoking
O	1955	1957	or
O	1958	1965	obesity
O	1965	1966	.

O	1967	1976	Promoting
O	1977	1980	QOL
O	1981	1984	and
O	1985	1993	managing
O	1994	2002	symptoms
O	2003	2008	early
O	2009	2011	in
O	2012	2019	therapy
O	2020	2023	may
O	2024	2026	be
O	2027	2036	important
O	2037	2047	strategies
O	2048	2050	to
O	2051	2058	improve
O	2059	2068	adherence
O	2068	2069	.
